中國環保科技(00646.HK)斥10萬元購生物細胞存儲商51%權益
中國環保科技(00646.HK)公佈,其全資子公司Winsum Investment,向Zhong Shen Cambodia和楊彩雲收購目標公司柬中生物研究控股之51%的權益,交易對價爲10萬元(應以現金支付)。
目標集團之主要業務爲生物細胞存儲服務,生物冷鏈物流,生物諮詢服務,銷售及交流及推廣生物科技以及銷售醫療器械、生物資料和保健產品。其與廣東韶關市武江區政府簽訂一份意向協議,將聯合其他合作方一起在廣東韶關武江區投資建設NSCTRC靈長類動物儲備實驗中心。
公司認爲,通過簽訂買賣協議,收購將擴展集團服務細胞生物行業的能力。另指出,監於目前的財務狀況,董事會決定將其現時健康相關業務從爲開發新藥進行研發和服務於細胞相關研發,改變爲專注於擴大其服務細胞和其他生物醫學行業板塊的能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.